{
  "success": true,
  "pagesUsed": [
    15,
    16,
    17,
    21,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of daratumumab plus Rd (DRd) over Rd alone in terms of progression-free survival (PFS)",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - OS",
        "text": "To evaluate overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - MRD",
        "text": "To assess MRD negativity rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Response",
        "text": "Time to response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Objective - MRD Durability",
        "text": "Durability of MRD negativity",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-free survival",
        "text": "Progression-free survival (PFS) per International Myeloma Working Group (IMWG) criteria",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival",
        "text": "Overall survival (OS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "MRD Negativity Rate",
        "text": "MRD negativity rate, defined as the proportion of subjects assessed as MRD negative, at any timepoint after the date of randomization",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Time to Response",
        "text": "Time to response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Durability of MRD Negativity",
        "text": "Durability of MRD negativity",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand for PFS",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment",
            "text": "Subject discontinues study treatment for reasons other than disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause prior to disease progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Progression-free survival (PFS) per IMWG criteria",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Overall Survival Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment Switching (Crossover)",
            "text": "Subjects in Arm A (Rd) receiving daratumumab after confirmed disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Overall survival (OS)",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "MRD Negativity Rate Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Odds ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death or Disease Progression",
            "text": "Death or disease progression before achieving MRD negativity",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "MRD negativity rate at any timepoint after randomization",
        "summaryMeasure": "Odds ratio"
      },
      {
        "id": "est_4",
        "name": "Time to Response Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Median time to response.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death without response",
            "text": "Subject dies before achieving a response",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Time to response",
        "summaryMeasure": "Median time to response"
      },
      {
        "id": "est_5",
        "name": "Durability of MRD Negativity Estimand",
        "populationSummary": "Subjects who achieved MRD negativity Summary measure: Median duration.",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Loss of MRD negativity or Death",
            "text": "Subject loses MRD negative status or dies",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Subjects who achieved MRD negativity",
        "variableOfInterest": "Durability of MRD negativity",
        "summaryMeasure": "Median duration"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 1,
      "totalEndpoints": 5,
      "totalEstimands": 5
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of daratumumab plus Rd (DRd) over Rd alone in terms of progression-free survival (PFS)",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - OS",
        "text": "To evaluate overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - MRD",
        "text": "To assess MRD negativity rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Response",
        "text": "Time to response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Objective - MRD Durability",
        "text": "Durability of MRD negativity",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-free survival",
        "text": "Progression-free survival (PFS) per International Myeloma Working Group (IMWG) criteria",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival",
        "text": "Overall survival (OS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "MRD Negativity Rate",
        "text": "MRD negativity rate, defined as the proportion of subjects assessed as MRD negative, at any timepoint after the date of randomization",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Time to Response",
        "text": "Time to response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Durability of MRD Negativity",
        "text": "Durability of MRD negativity",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand for PFS",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment",
            "text": "Subject discontinues study treatment for reasons other than disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause prior to disease progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Progression-free survival (PFS) per IMWG criteria",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_2",
        "name": "Overall Survival Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment Switching (Crossover)",
            "text": "Subjects in Arm A (Rd) receiving daratumumab after confirmed disease progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Overall survival (OS)",
        "summaryMeasure": "Hazard ratio"
      },
      {
        "id": "est_3",
        "name": "MRD Negativity Rate Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Odds ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death or Disease Progression",
            "text": "Death or disease progression before achieving MRD negativity",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "MRD negativity rate at any timepoint after randomization",
        "summaryMeasure": "Odds ratio"
      },
      {
        "id": "est_4",
        "name": "Time to Response Estimand",
        "populationSummary": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population) Summary measure: Median time to response.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death without response",
            "text": "Subject dies before achieving a response",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Adult patients with multiple myeloma meeting eligibility criteria (ITT population)",
        "variableOfInterest": "Time to response",
        "summaryMeasure": "Median time to response"
      },
      {
        "id": "est_5",
        "name": "Durability of MRD Negativity Estimand",
        "populationSummary": "Subjects who achieved MRD negativity Summary measure: Median duration.",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Loss of MRD negativity or Death",
            "text": "Subject loses MRD negative status or dies",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd)",
        "analysisPopulation": "Subjects who achieved MRD negativity",
        "variableOfInterest": "Durability of MRD negativity",
        "summaryMeasure": "Median duration"
      }
    ]
  }
}